Generated by AI
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven and immune-mediated diseases. The company’s lead program, briquilimab, is a monoclonal antibody designed to target the CD117 pathway and reduce mast cell activity, supporting research in conditions such as chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics also works on hematopoietic stem cell-based approaches, including conditioning regimens intended to support stem cell transplantation and ex vivo gene therapy. Its current business is centered on clinical development, translational research, and advancing therapeutic candidates for patients with serious inflammatory, immunological, and transplant-related disorders. Headquartered in Redwood City, California, Jasper Therapeutics operates in the biotechnology sector and focuses on programs that aim to address high unmet medical needs through targeted biological therapies.
Website2200 Bridge Pkwy
Redwood City, CA, 94065
United States
The latest articles about JSPR.
Summary of Jul 17's posts. Generated by AI.
Summary of Jul 17's posts. Generated by AI.
Summary of Oct 13's posts. Generated by AI.
Summary of Jul 17's posts. Generated by AI.
Investors talking about JSPR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.